Back to Search
Start Over
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.
- Source :
-
Nature communications [Nat Commun] 2024 Aug 27; Vol. 15 (1), pp. 7357. Date of Electronic Publication: 2024 Aug 27. - Publication Year :
- 2024
-
Abstract
- Image-guided percutaneous cryoablation is an established minimally invasive oncologic treatment. We hypothesized that cryoablation may modify the immune microenvironment through direct modulation of the tumor, thereby generating an anti-tumor response in tumors refractory to immune checkpoint inhibition (ICI). In this non-randomized phase II single-center study (NCT03290677), subjects with unresectable melanoma progressing on ICI underwent cryoablation of an enlarging metastasis, and ICI was continued for a minimum of two additional cycles. The primary endpoints were safety, feasibility and tumor response in non-ablated lesions. From May 2018 through July 2020, 17 patients were treated on study. The study met its primary endpoints with the combination strategy found to be safe and feasible with an objective response rate of 23.5% and disease control rate of 41% (4 partial response, 3 stable disease). Our data support further study of this synergistic therapeutic approach.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Female
Male
Middle Aged
Aged
Disease Progression
Adult
Skin Neoplasms drug therapy
Skin Neoplasms pathology
Skin Neoplasms immunology
Skin Neoplasms surgery
Tumor Microenvironment immunology
Neoplasm Metastasis
Treatment Outcome
Combined Modality Therapy
Aged, 80 and over
Melanoma drug therapy
Melanoma pathology
Melanoma surgery
Melanoma immunology
Immune Checkpoint Inhibitors therapeutic use
Cryosurgery methods
Subjects
Details
- Language :
- English
- ISSN :
- 2041-1723
- Volume :
- 15
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Nature communications
- Publication Type :
- Academic Journal
- Accession number :
- 39191779
- Full Text :
- https://doi.org/10.1038/s41467-024-51722-x